# **Annex 11B. Incremental Progress Report** (IPR) for EUPHEM fellows

From: Name

**Cohort:** Cohort number **Training site supervisor:** Name of supervisor

**Update from:** Current Date

Note: please indicate changes from last IPR in red

1) Administrative Matters:

Date:	Topic:	Status:	Please describe procedure, difficulties, timelines and reason for not completing
Put date	List and comment on administrative issues relevant to the training programme (salaries, insurance, hosting office, communication means, reimbursements etc.). Please mention your meetings with your supervisors dated and also communication with your frontlines on your outputs, IPR,etc	Put status (starting, ongoing, completed)	

2) Outbreak Investigations:

Date:	Type of outbreak and your involvement:	Status:	Please describe procedure, difficulties, timelines and reason for not
Put date	Describe any involvement in outbreak investigations. Each completed outbreak investigation should be detailed in a summary <15 lines (context, investigation team, objectives, methods, results, conclusion, recommendations and actions). Please state also your role and if you were main investigator. Main investigator: Yes/No	Put status (starting, ongoing, completed)	completing

3) Surveillance Activities:

Date:	Type of surveillance and your involvement:	Status:	Please describe procedure, difficulties, timelines and reason for not
Put date	Summarise activities related to epidemiological surveillance, including protocols, data analysis and reports developed to set up surveillance systems, evaluation schemes and results of surveillance data analyses. Please state also your role.	Put status (starting, ongoing, completed)	completing

4) Research Activities:

Date:	Type of research and your involvement:	Status:	Please describe procedure, difficulties, timelines and reason for not completing
Put date	Summarise research protocols, study reports or manuscripts written during the last three months. The summary should include: objectives, methods, results, recommendations and public health impact. Please state also your role.	Put status (starting, ongoing, completed)	

5) Biosafety/biosecurity activities

J) blosalet	// blosecurity activities		
Date:	Type of activity and your involvement:	Remarks:	Please describe procedure, difficulties, timelines and reason for not completing
Put date	List the context and content of various activities which you helped to plan, develop or undertook. State the objectives, content, audience and location of the activity.	Put status (starting, ongoing, completed)	

## 6) Quality management

Date:	Type of activity and your involvement:	Remarks:	Please describe procedure, difficulties, timelines and reason for not completing
Put date	List the context and content of various activities which you helped to plan, develop or undertook. State the objectives, content, audience and location of the activity.	Put status (starting, ongoing, completed)	

7) Training activities:

Date:	Type of training followed:	Status:	Please describe procedure, difficulties, timelines and reason for not completing	
Put date	<ul> <li>a) List all training sessions which you attended during the reporting period, and include comments on their content. This information should also help to publicise training site or host country training opportunities.</li> </ul>	Put status (starting, ongoing, completed)		
	b) List the optional EPIET modules you have attended. Compulsory modules do not need to be mentioned.			

<ul> <li>Include the visits to the laboratories.</li> <li>Specify the length and the type of activities you were involved with.</li> </ul>		

8) Teaching Activities:

o) reaching	ACTIVITIES.		
Date:	Type of teaching and your involvement:	Remarks:	Please describe procedure, difficulties, timelines and reason for not completing
Put date	List the context and content of various teaching sessions which you helped to plan, develop or undertook. State the objectives, content, audience and location of the courses.	Put status (starting, ongoing, completed)	

9) Management and Communication:

9) Manage	ment and Communication:		
Date:	Type of communication (including publications and presentations):	Remarks:	Please describe procedure, difficulties, timelines and reason for not completing
Put date	<ul> <li>a) List all on call/ telephone help-line duties, TV and radio interviews, question and answers briefs, preparation of press releases, public health decision and policymaking sessions, oral scientific presentation, and poster presentations. List all scientific reports and manuscripts in preparation.</li> </ul>	Put status (starting, ongoing, completed)	
	<ul> <li>b) List all publications, referenced using         Vancouver style and organised according to type of article and type of journal:         <ul> <li>Epidemiological bulletin</li> <li>National or regional journals (state whether peer-reviewed)</li> <li>International journals</li> </ul> </li> </ul>		

10) Other:

10) Otner:			
Date:	Type of activity and your involvement:	Remarks:	Please describe procedure, difficulties, timelines and reason for not completing
Put date	Short description of any other activity and your involvement	Put status (starting, ongoing, completed)	

# **Example of progress report (please notice difference in current version format)**

From: Xxxx Xxxx, EUPHEM Fellow C1
Cohort: 1

**Update from:** 18.8.2010

1) Administrative Matters:

Date:	Topic:	Status:
Date.	Topic.	Status.
2.11.2008	Found a flat and moved in. Opened local bank account.	Completed
05.11.2008	Submitted the following documents to ECDC: Financial	Completed
	Identification, Daily allowance request, Travel imbursement	
	request	
25.3.2009	Installation allowance received.	Completed
11.8.2010	David Brown has sent an outline of the specific activities of my	Completed
	EUPHEM fellowship to the responsible body of the medical	
	microbiology specialist training at the Faculty of Medicine in	
	Helsinki. They will review activities that could be counted in	
	benefit of the Finnish specialist training scheme.	

2) Outbreak Investigations:

	nvestigations:	-
Date:	Type of outbreak and your involvement:	Status:
28.45.5.09	General pandemic (H1N1) 2009 activities  Worked as a liaison between laboratory and epidemiologists at the Emergency Operations Centre of CfI.  • Adviced epidemiologists and local health protection	Completed
	units on e.g. sampling, specimen materials, storage and transportation of specimens, timing of sampling, turnaround time, logistics, subtyping, antibody kinetics, and effect of previous immunity to the tests, testing of recovered cases	
	Helped in composing information for the public concerning laboratory tests. Picked video footage filmed in the lab for national television channels.	
	Adviced on laboratory safety issues and containment level.	
	Adviced attending physicians of confirmed cases on required futher specimens	
	Participated in writing Q&A for regional laboratories	
6.5.2009	Wrote an <b>overview of currently available Influenza A/H1N1 Virus Biosafety Guidelines for Laboratories</b> . This functioned as a background material for the discussions between the CfI and the Health and Safety Executive (HSE) on laboratory safety issues regarding H1N1.	Completed
7.5.2009	Wrote an <b>overview of currently available data on clinical manifestations and complications</b> associated with Influenza A/H1N1 virus.	Completed
May-July 2009	Pandemic (H1N1) 2009 Outbreak investigation in a school in London: observational descriptive study (with	
2003	Laurence)	Completed
	<ul><li>Data collection</li><li>Data cleaning</li></ul>	Completed
	Data cleaning     Data analysis	Completed 12.5.2009
	Preliminary epidemiological report	Completed
	, , , , , , , , , , , , , , , , , , , ,	Completed

	<ul><li>Final report</li><li>Journal article manuscript</li></ul>	Published 1/2010
15.10.2009	Preparation of generic protocol for possible future H1N1 school outbreaks in the UK, including serosurveys.	Completed

3) Surveillance Activities:

3) Surveillance Activities:		
Date:	Type of surveillance and your involvement:	Status:
1/2009- 5/2010	Creating a microbiological syndrome-based surveillance system for the detection and investigation of undiagnosed serious infectious illnesses (USII)  • Major microbiological challenges identified	Completed from my part (project ongoing)
	<ul> <li>Presented the first draft of the protocol to the working group on 2 April 2009 and further actions were decided.</li> </ul>	
	<ul> <li>Checklist for firstline investigations created for all five syndromes.</li> </ul>	
1-8/2010	HAV seroepidemiology in Europe (ESEN2 project)	
	The epidemiology of Hepatitis A virus (HAV) is known to vary geographically. Only scattered data are available on HAV seroepidemiology in Europe, and uncertainties exist about the age-specific susceptibility and average age of infection. Aim: to identify susceptible age groups and level of endemicity to inform HAV vaccination policy in the participating countries: Belgium, Czech Republic, England, Finland, Germany, Italy, Lithuania, Malta, Romania, and Slovakia. Each country tested sera (n=1854–6748), collected in 1996–2004 as residual sera remaining from routine laboratory testing (7/10 countries), or by population-based random sampling (3/10), for total HAV antibodies. The local laboratory results were standardised to common units. Information on disease epidemiology and vaccine policy was collected.  Data cleaning and analysis  Manuscript and abstract  Awaiting comments on the manuscript from country representatives (co-authors)	Completed 3/2010 Under preparation On-going

4) Research Activities:

Type of research and your involvement:	Status:
Investigation on the public health significance of newly	Project frozen
zoonotic and public health risk assessments of Saffold	
and Ljungan viruses; Develop and evaluated molecular	
pathogens in laboratory	
The methodology has been developed with the help of related Mengovirus.	
	Investigation on the public health significance of newly identified picornaviruses in humans. Approaches: Conduct zoonotic and public health risk assessments of Saffold and Ljungan viruses; Develop and evaluated molecular and/or serological tools to investigate infection with these agents in human samples; Design study to assess prevalence of infections and any disease association.  • Major challenges are now gaining access to the virus strains used in the tests and the serum sample archives. Ljungan virus infectious clone has arrived to the lab, Ljungan virus culture supernatant will arrive within a week. Saffold: ? May take several months to gain access to the serum sample archives.  • Crude sample size calculations are being done  • Wrote COSHH risk assessment for handling these pathogens in laboratory  • The methodology has been developed with the help

3.4.2009	Mumps seroprevalence and correlates of protection study, mumps outbreak Moldova, 2007- 2008.	Cancelled
15.1.2010	Reconstructing transmission trees from partially observed epidemic trees in a pandemic (H1N1) 2009 school outbreak. Data from the abovementioned H1N1 school outbreak are being used for modelling of transmission events in a school setting. This analysis allows e.g. estimation or reproductive numbers by time from onset of symptoms. My role with Laurence is to assist the modellers to understand and interpret our data. Analysis is finished and manuscript is under preparation.	Manuscript under preparation
8/2009- 5/2010	Public health significance of Hantaviruses in the UK. The hosts of hantaviruses Puumala (Myodes glareolus), Dobrava (Apodemus flavivollis) and Seoul (Rattus) are present in UK and these viruses, particularly Puumala virus, are widely found in their hosts in mainland Europe. In the UK, uncertainties exist about the presence of hantaviruses. Aim: to identify hantavirus infections in clinically suspected patients to contribute to assessing the public health significance of hantaviruses in the UK.  • Preparatory work  • sample shipment  • pre-planning the lab work in Helsinki  • Testing of specimens  • Screening of convalescent sera for Avricolinae-borne hantavirus antibodies with Puumala IgG immunofluorescence assay (IFA), and for Murinae-borne hantavirus antibodies with Dobrava-Saaremaa IgG IFA.  • In case of (specific or unspecific) reactivity in IgG testing, the convalescent samples underwent Puumala IgM (bac-PUU-N) ELISA, and both samples Puumala and Dobrava-Saaremaa IgM IFA.  • Short report  • Abstract	Completed 3/2010 Completed 4/2010  Completed 5/2010 Submitted

5) Training activities:

Type of training followed:	Status:
<i>,</i> ,,	
	Completed
	Completed
	Completed
	Completed
EPIET CTOI module, <b>Cyprus</b>	Completed
Pointers conference (on blood borne infections in	Completed
health care workers), <b>London</b>	
Rabies training, CfI	Completed
Train the trainer level course on Containment Level 3	Completed
Laboratory, Porton Down, <b>Salisbury</b>	
	Completed
	·
, J	
	Completed
Video Training session on working in CL3 laboratory,	Completed
CfI	
Induction training session for Containment Level 3	Completed
Laboratory, CfI	
EPIET Vaccinology module, <b>Helsinki</b>	Completed
ENIVD-CLRN annual meeting, <b>Prague</b>	Completed
	Completed
	Completed
certificate	,
EPIET Rapid Assesment module, <b>Bristol</b>	Completed
	Completed
	Type of training followed:  EPIET introductory course, Menorca  Lecture: Pandemic Influenza Preparedness, CfI  Journal Club, CfI (1h)  ESCAIDE conference, Berlin  EPIET CTOI module, Cyprus  Pointers conference (on blood borne infections in health care workers), London  Rabies training, CfI  Train the trainer level course on Containment Level 3  Laboratory, Porton Down, Salisbury  Wellcome Trust Advanced Course: Virus discovery in Clinical Setting, Cambridge  Journal Club, CfI (1h)  Video Training session on working in CL3 laboratory, CfI  Induction training session for Containment Level 3  Laboratory, CfI  EPIET Vaccinology module, Helsinki  ENIVD-CLRN annual meeting, Prague  Basic Security in the Field, UN training and certificate  Advanced Security in the Field, UN training and

31.84.9.2009	EUPHEM project review module, Rome	Completed
1416.9.2009	Health Protection 2009 conference, University of Warwick, <b>Coventry</b> , <b>UK</b>	Completed
69.10.2009	ECDC PRU Briefing, <b>Stockholm</b>	Completed
16.10.2009	HPA Encephalitis Study Grand Finale, BMA House, London	Completed
2628.10.2009	ESCAIDE conference, <b>Stockholm</b>	Completed
25-26.2.2010	UK mini project review, <b>CfI, London</b>	Completed
9.3.2010	Journal Club, CfI (1h)	Completed
29.39.4.2010	Laboratory quality assurance and tools for survey and control of tropical diseases (module of Masters of International Health 2009-2010 Erasmus Mundus: tropical diseases), <b>Bordeaux, France</b>	Completed
1012.6.2010	ENIVD-CLRN annual meeting, <b>Stockholm</b>	Completed
27.7.2010	European Workshop on Laboratory Diagnosis of Diphtheria (Lectures), <b>CfI, London</b>	Completed
7-8/2010	<ul> <li>A 5-week introduction round in the different units of the bacteriology department of the HPA/Centre for Infections, including:         <ul> <li>Antibiotic Resistance Monitoring &amp; Reference Laboratory</li> <li>Department for Bioanalysis and Horizon Technologies</li> <li>Haemophilus reference unit</li> <li>Streptococcus and Diphtheria Reference Unit</li> <li>Laboratory of Health Care Associated Infection</li> </ul> </li> </ul>	Completed
30.83.9.2010	EUPHEM-EPIET project review module, Rome	Upcoming
1415.9.2010	Health Protection 2010 conference, University of Warwick, <b>Coventry, UK</b>	Upcoming
1113.11.2010	ESCAIDE conference, <b>Lisbon</b>	Upcoming

6) Teaching Activities:

6) Teaching Activ	/IUCS.	
Date:	Type of teaching and your involvement:	Remarks:
2327.2.2009	Gave a lecture and facilitated in case study sessions in the "Laboratory Essentials for Field Epidemiologists" EPIET module, Bilthoven, Netherlands • Lecture: Virus diagnostic methods • Case study: Atypical pneumonia in a city in the Netherlands (Legionella)	Completed
15.3.2010	<b>Group facilitation</b> , "Vaccinology", London School of Hygiene and Tropical Medicine	Completed
Preparation: 4-9/2010 Module: 810.9.2010	UK Lab4epi module for local EPIET fellows and SpR:s. The aim is also to create a frame for future Lab4epi modules as to programme and training material. Organisation of the module together with Sabine Dittrich and Marie-Amelie Degail.  • Preparation of the module programme (with MAD and SD)  • Objectives  • Lecture topics  • Case study topic  • Order and timing of sessions  • Facilitators/lecturers  • Evaluation  • Modification of an existing case study and preparation of supporting material to fit the purpose of the module (with SD). Facilitation of the case study during the module.	Preparation ongoing

<ul> <li>Lecture: Factors influencing a laboratory test result (by myself)</li> <li>Lecture: What is a public health laboratory? (with SD)</li> <li>Lecture: Using diagnostic tests for public health decision making (with SD)</li> </ul>	
Interactive session to familiarise participants on commont <i>lab terminology</i> (with SD)	

#### 7) Communication:

7) Communic		Domaylar
Date:	Type of communication (including publications and presentations):	Remarks:
15.5.2009	Presentation:	Presented
	"EUPHEM training activities at HPA, London"	
	ENIVD-CLRN annual meeting, Prague	
9.7.2009	Draft proposal on assessing the public health significance of arthropod-borne and rodent-borne viruses in the UK, including a risk assessment. To be presented for the Department of Health.	Presented
28.7.2009	Presentation:	Presented
	"Pandemic (H1N1) 2009 virus outbreak in a school in London, April-May 2009:observational study"	
	EPIET Seminar on H1N1 Investigations, ECDC, Stockholm	
15.9.2009	Conference abstract:	Presented (poster)
	L Calatayud, S Kurkela, P Neave, A Brock, S Perkins, M Zuckerman, M Catchpole, R Pebody, R Heathcock, H Maguire. New Influenza A(H1N1) Virus Outbreak in a School, South-East London, April-May 2009. <b>Health Protection 2009, Coventry, UK</b>	
27.10.2009	Conference abstract:	Presented (oral by LC)
	L Calatayud, S Kurkela, P Neave, A Brock , S Perkins, M Zuckerman, M Catchpole, R Pebody, R Heathcock, H Maguire. New Influenza A(H1N1) Virus Outbreak in a School, South-East London, April-May 2009. <b>ESCAIDE, Stockholm, Sweden</b>	
1.9.2009	Review article:	Published
	Kurkela S, Brown DWG. Molecular diagnostic techniques. <b>Medicine 2009;37:535-40.</b>	
7.10.2009	Presentation:	Presented
	"Pandemic (H1N1) 2009 virus outbreak in a school in London, April-May 2009". <b>ECDC PRU briefing week, ECDC, Stockholm</b>	
5.1.2010	Journal article:	Published
	Calatayud L, Kurkela S, Neave PE, Brock A, Perkins S, Zuckerman M, Sudhanva M, Bermingham A, Ellis J, Pebody R, Catchpole M, Heathcock R, Maguire H. Pandemic (H1N1) 2009 virus outbreak in a school in London: observational study. <b>Epidemiol Infect 2010;138:183-91.</b>	
25.3.2010	Presentation:	Presented
	"First experiences from the EUPHEM programme"	

	The 6 <sup>th</sup> National Focal Point Meeting, ECDC, Stockholm, Sweden	
7.5.2010	Factsheet:	Completed
	Preparation of <b>ECDC Factsheet on Sindbis virus infection</b> with ECDC PRU.	
13.5.2010	Presentation:	Presented
	Comparative Hepatitis A Seroepidemiology in 10 European Countries. <b>SpR Meeting, CfI.</b>	
26.5.2010	Book chapter:	Pre-final draft submitted
	Kurkela S, Brown DWG. Foot-and-mouth Disease, Vesicular Stomatitis, Newcastle Disease, and Swine Vesicular Disease. In: <b>Zoonoses - biology, clinical practice and public health control, 2nd Edition</b> , (SR Palmer, Lord Soulsby, David Brown, and Paul Torgerson, Editors). Oxford University Press. Oxford. U.K. Under preparation.	
11.6.2010	Presentation:	Presented
	EUPHEM training activities 2008-2010. <b>ENIVD-CLRN</b> annual meeting, <b>Stockholm</b>	
18.8.2010	Journal article manuscript:	Under preparation
	Kurkela S, Pebody R, Kafatos G, Nardone A, Andrews N, Pistol A, Davidkin I, Vranckx R, Nemecek V, Hesketh LM, Thierfelder W, Bruzzone B, Griskevicius A, Barbara C, Sobotova Z, Miller E, Hatzakis A, Anastassopoulou CG. Comparative Hepatitis A Seroepidemiology in 10 European Countries.	
14.9.2010	Conference abstract/Presentation:	Upcoming; abstract
	Comparative Hepatitis A Seroepidemiology in 10 European Countries. <b>Health Protection 2010 conference, Coventry, UK</b>	accepted for oral presentation
Nov 2010	Conference abstract/Presentation:	Upcoming; abstract
	Kurkela S, Pebody R, Kafatos G, Nardone A, Andrews N, Pistol A, Davidkin I, Vranckx R, Nemecek V, Hesketh LM, Thierfelder W, Bruzzone B, Griskevicius A, Barabara C, Sobotova Z, Miller E, Hatzakis A, Anastassopoulou CG. Comparative Hepatitis A Seroepidemiology in 10 European Countries.	accepted for oral presentation
Nov 2010	Conference abstract:	Upcoming; abstract
	Kurkela S, Brown D, Vapalahti O, Sivaprakasam V, Zochowski W, Smith R. No evidence of hantavirus infections in a series of 90 clinically suspected patients in the UK.	accepted for poster presentation

### 8) Other:

Date:	Type of activity and your involvement:	Remarks:
12.11.2008	Wrote a report on the potential human pathogenicity of	Completed
	Ljungan virus	
13.12.2008	Attended teleconferences regarding a fatal <b>anthrax</b> case in London.	Completed
28.2.2009	Wrote a <b>short introduction to EUPHEM</b> programme to EAN newsletter together with Sabine Dittrich	Completed
2.4.2009	Wrote a compulsory <b>COSHH risk assessment</b> for handling Saffold and Ljungan viruses in laboratory.	Completed

1.4.2009	Prepared a presentation "Impact and effectiveness of Hib vaccine in the UK" for the vaccinology module together with Jaran, Otilia and Laurence	Completed
4.11.2009	Identified and translated Finnish guidelines on diagnosis and treatment of Lyme borreliosis for a working group (lead by Dr Susan O'Connell at the Lyme Borreliosis Unit in Southampton). The working group is collecting a complete set of European guidelines.	Completed
2425.3.2010	Participated in <b>the 6<sup>th</sup> National Focal Point Meeting at ECDC</b> • Presentation (see above) and panel discussion (EUPHEM issues)  • Working group moderation (EUPHEM issues)  • Observation of the meeting (non-EUPHEM issues)	Completed